X

Drug Profile

Anti-mesothelin CAR T cell therapy - Tmunity Therapeutics

Alternative Names: TmMSTN-02

Latest Information Update: 26 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tmunity Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer

Most Recent Events

22 Feb 2023 Tmunity Therapeutics has been acquired by Kite Pharma
10 Feb 2021 Anti-mesothelin CAR T cell therapy - Tmunity Therapeutics is available for licensing as of 10 Feb 2021. https://www.tmunity.com/
30 Dec 2020 Preclinical trials in Lung cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com